Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Cancer Treatment-Induced Thrombocytopenia in Hematologic Malignancies
ChiCTR2600117997Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Time to Platelet Recovery. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on ChiCTR2600117997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117997.